Clinical Trial Update: Use of NovoSeven® in Active Variceal Bleeding [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating NovoSeven (recombinant activated factor VII) for active variceal bleeding in patients with cirrhosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorder
• Cirrhosis

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Cirrhosis | Phase 2 | Status: COMPLETED